

Helen Giza

Chief Executive Officer

Member of the Management Board since: November 1, 2019

Appointed until: May 15, 2027

Personal data:

Born: 1968
Gender: Female
Nationality: British / U.S.
Education: Chartered Certified Accountant (Great Britain)
Master of Business Administration
Kellogg School of Management, Northwestern University, Evanston, Illinois,
U.S.

Professional experience:**Fresenius Medical Care AG¹**

2022 – present Chief Executive Officer and Chairwoman of the Management Board
2022 – 2023 acting Chief Financial Officer
2021 – 2022 Chief Transformation Officer
2019 – 2022 Chief Financial Officer

Takeda Pharmaceuticals Company Limited

2018 – 2019 Chief Integration & Divestiture Management Officer
2015 – 2018 Senior Vice President, Chief Financial Officer – U.S. Business Unit
2008 – 2015 Vice President, Chief Financial Officer – U.S. Business Unit

TAP Pharmaceutical Products Inc.

2005 – 2008 Vice President & Division Controller
2004 – 2005 Assistant Controller

Abbott Laboratories

2003 – 2004 Area Controller Commercial – Asia Pacific Region
1999 – 2003 Finance Manager – Manufacturing Operations

Dana Incorporated

1996 – 1999 Finance Director

ITT, Inc.

1991 – 1996 Cost Accountant

Membership in supervisory board or comparable supervisory bodies:²**Board of Directors**

Fresenius Medical Care Holdings, Inc., U.S.³
Resonetics, LLC, U.S.

Board of Administration

Vifor Fresenius Medical Care Renal Pharma Ltd., Switzerland

¹ For the period until the change of the legal form of the Company from Fresenius Medical Care AG & Co. KGaA to Fresenius Medical Care AG, the information relates to the activity as a member of the Management Board of Fresenius Medical Care Management AG in its function as General Partner of the Company at that time.

² Non-executive Director. Unless stated otherwise, the companies are not public.

³ Fresenius Medical Care Group mandate